Bioxytran, Inc. (BIXT)
USD 0.14
(8.73%)
USD 0.14
(8.73%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 3.24 Million USD | -11.3% |
| 2022 | 3.66 Million USD | 11.78% |
| 2021 | 3.27 Million USD | 44.53% |
| 2020 | 2.26 Million USD | 122.56% |
| 2019 | 1.01 Million USD | 289.31% |
| 2018 | 261.72 Thousand USD | 42.8% |
| 2017 | 183.27 Thousand USD | -46.45% |
| 2016 | 342.26 Thousand USD | 36.34% |
| 2015 | 251.03 Thousand USD | -25.0% |
| 2014 | 334.73 Thousand USD | 82.93% |
| 2013 | 182.98 Thousand USD | 146.05% |
| 2012 | 74.37 Thousand USD | 40.83% |
| 2011 | 52.81 Thousand USD | -61.38% |
| 2010 | 136.74 Thousand USD | -14.67% |
| 2009 | 160.26 Thousand USD | 678.13% |
| 2008 | 20.59 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 1.24 Million USD | 1.23% |
| 2024 Q2 | 1.22 Million USD | 10.09% |
| 2024 Q1 | 1.11 Million USD | -65.66% |
| 2023 Q3 | 2.33 Million USD | -15.75% |
| 2023 Q1 | 4.29 Million USD | 17.21% |
| 2023 FY | 3.24 Million USD | -11.3% |
| 2023 Q4 | 3.24 Million USD | 39.29% |
| 2023 Q2 | 2.76 Million USD | -35.51% |
| 2022 Q1 | 4.88 Million USD | 49.12% |
| 2022 Q2 | 5.32 Million USD | 9.04% |
| 2022 Q3 | 2.99 Million USD | -43.75% |
| 2022 Q4 | 3.66 Million USD | 22.21% |
| 2022 FY | 3.66 Million USD | 11.78% |
| 2021 Q3 | 2.67 Million USD | 21.03% |
| 2021 FY | 3.27 Million USD | 44.53% |
| 2021 Q4 | 3.27 Million USD | 22.33% |
| 2021 Q1 | 2.87 Million USD | 26.93% |
| 2021 Q2 | 2.21 Million USD | -23.09% |
| 2020 Q1 | 1.88 Million USD | 84.61% |
| 2020 Q3 | 2.09 Million USD | 9.94% |
| 2020 FY | 2.26 Million USD | 122.56% |
| 2020 Q4 | 2.26 Million USD | 8.34% |
| 2020 Q2 | 1.9 Million USD | 1.22% |
| 2019 Q1 | 773.82 Thousand USD | 195.66% |
| 2019 FY | 1.01 Million USD | 289.31% |
| 2019 Q2 | 702.18 Thousand USD | -9.26% |
| 2019 Q3 | 1.21 Million USD | 72.87% |
| 2019 Q4 | 1.01 Million USD | -16.06% |
| 2018 Q2 | 150.1 Thousand USD | -16.11% |
| 2018 Q3 | 52.6 Thousand USD | -64.95% |
| 2018 Q1 | 178.92 Thousand USD | -2.37% |
| 2018 FY | 261.72 Thousand USD | 42.8% |
| 2018 Q4 | 261.72 Thousand USD | 397.49% |
| 2017 Q2 | 415.39 Thousand USD | 8.06% |
| 2017 FY | 183.27 Thousand USD | -46.45% |
| 2017 Q3 | 421.71 Thousand USD | 1.52% |
| 2017 Q4 | 183.27 Thousand USD | -56.54% |
| 2017 Q1 | 384.4 Thousand USD | 12.31% |
| 2016 Q2 | 268.45 Thousand USD | -2.89% |
| 2016 FY | 342.26 Thousand USD | 36.34% |
| 2016 Q4 | 342.26 Thousand USD | -0.13% |
| 2016 Q3 | 342.7 Thousand USD | 27.66% |
| 2016 Q1 | 276.45 Thousand USD | 10.12% |
| 2015 Q4 | 251.03 Thousand USD | 41.73% |
| 2015 FY | 251.03 Thousand USD | -25.0% |
| 2015 Q1 | 358.12 Thousand USD | 6.99% |
| 2015 Q2 | 405.65 Thousand USD | 13.27% |
| 2015 Q3 | 177.12 Thousand USD | -56.34% |
| 2014 Q1 | 199.43 Thousand USD | 8.99% |
| 2014 FY | 334.73 Thousand USD | 82.93% |
| 2014 Q4 | 334.73 Thousand USD | 11.32% |
| 2014 Q3 | 300.7 Thousand USD | 16.01% |
| 2014 Q2 | 259.2 Thousand USD | 29.97% |
| 2013 Q4 | 182.98 Thousand USD | -73.64% |
| 2013 FY | 182.98 Thousand USD | 146.05% |
| 2013 Q1 | 152.07 Thousand USD | 104.49% |
| 2013 Q2 | 432.82 Thousand USD | 184.61% |
| 2013 Q3 | 694.16 Thousand USD | 60.38% |
| 2012 Q4 | 74.37 Thousand USD | 5.5% |
| 2012 FY | 74.37 Thousand USD | 40.83% |
| 2012 Q1 | 117.04 Thousand USD | 121.63% |
| 2012 Q2 | 77.3 Thousand USD | -33.95% |
| 2012 Q3 | 70.49 Thousand USD | -8.81% |
| 2011 Q2 | 172.63 Thousand USD | 50.76% |
| 2011 FY | 52.81 Thousand USD | -61.38% |
| 2011 Q3 | 94.63 Thousand USD | -45.18% |
| 2011 Q4 | 52.81 Thousand USD | -44.2% |
| 2011 Q1 | 114.51 Thousand USD | -16.26% |
| 2010 Q3 | 103.82 Thousand USD | -15.77% |
| 2010 Q2 | 123.27 Thousand USD | -40.71% |
| 2010 Q1 | 207.92 Thousand USD | 29.74% |
| 2010 FY | 136.74 Thousand USD | -14.67% |
| 2010 Q4 | 136.74 Thousand USD | 31.71% |
| 2009 FY | 160.26 Thousand USD | 678.13% |
| 2009 Q2 | 37.02 Thousand USD | 11.25% |
| 2009 Q3 | 106.23 Thousand USD | 186.9% |
| 2009 Q1 | 33.28 Thousand USD | 0.0% |
| 2009 Q4 | 160.26 Thousand USD | 50.86% |
| 2008 FY | 20.59 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Evofem Biosciences, Inc. | 72.47 Million USD | 95.516% |
| Neon Bloom, Inc. | 1.22 Million USD | -165.003% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -301.771% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -7170.226% |
| Qrons Inc. | 1.48 Million USD | -118.276% |
| Rebus Holdings, Inc. | 5.24 Million USD | 38.01% |
| Skye Bioscience, Inc. | 14.07 Million USD | 76.908% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 94.494% |
| Adynxx, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 95.663% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -1515.734% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 65.672% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -11745.223% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 93.904% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 66.088% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -670.813% |
| SQZ Biotechnologies Company | 50.03 Million USD | 93.506% |
| Intellipharmaceutics International Inc. | 12 Million USD | 72.941% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 15.629% |
| Mesoblast Limited | 188.44 Million USD | 98.276% |
| Marizyme, Inc. | 26.67 Million USD | 87.819% |
| Genus plc | 485 Million USD | 99.33% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 44.383% |
| Pharming Group N.V. | 244.07 Million USD | 98.669% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -61.656% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -29.137% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 14.487% |
| ContraFect Corporation | 32.53 Million USD | 90.011% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -64.008% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 15.105% |
| IMV Inc. | 37.93 Million USD | 91.434% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 72.411% |
| MultiCell Technologies, Inc. | 1617.67 USD | -200775.333% |
| ONE Bio Corp. | 27.49 Million USD | 88.182% |
| Accustem Sciences Inc. | 1.07 Million USD | -201.092% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 95.803% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -53.636% |
| Q BioMed Inc. | 8.13 Million USD | 60.045% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 96.082% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 36.854% |
| Biomind Labs Inc. | 1.49 Million USD | -116.834% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 97.263% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 64.063% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 82.343% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -126.626% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -2186.85% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 43.446% |
| GB Sciences, Inc. | 5.41 Million USD | 40.019% |
| Alpha Cognition Inc. | 7.16 Million USD | 54.646% |
| HST Global, Inc. | 593.59 Thousand USD | -447.429% |
| CSL Limited | 18.62 Billion USD | 99.983% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -158.062% |
| Halberd Corporation | 728.71 Thousand USD | -345.919% |
| Enzolytics Inc. | 365.26 Million USD | 99.11% |
| Agentix Corp. | 2.51 Million USD | -29.434% |
| Resverlogix Corp. | 67.39 Million USD | 95.178% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -287.43% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 99.27% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -89.586% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 86.869% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 72.7% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 11.341% |
| AVAX Technologies, Inc. | 3.99 Million USD | 18.635% |
| Zenith Capital Corp. | 27.56 Thousand USD | -11686.79% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.755% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -1261.595% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 12.982% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -377.282% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -19.835% |
| Kadimastem Ltd | 3.5 Million USD | 7.286% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -4755.145% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 93.535% |
| BioStem Technologies, Inc. | 15.9 Million USD | 79.569% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -599.27% |
| LadRx Corporation | 2.2 Million USD | -47.669% |
| Cell Source, Inc. | 15.8 Million USD | 79.442% |
| Regen BioPharma, Inc. | 5.45 Million USD | 40.459% |
| Regen BioPharma, Inc. | 5.45 Million USD | 40.459% |
| NovAccess Global Inc. | 7.86 Million USD | 58.662% |
| Affymax, Inc. | 8.87 Million USD | 63.369% |
| Itoco Inc. | 1.65 Million USD | -96.564% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -58.391% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 46.28% |
| Mobile Lads Corp. | 1.31 Million USD | -147.393% |
| CytoDyn Inc. | 127.89 Million USD | 97.459% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -7674.109% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -107.453% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 70.58% |
| SYBLEU INC | 681.41 Thousand USD | -376.877% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 46.746% |
| International Stem Cell Corporation | 5.27 Million USD | 38.421% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -419.248% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 29.621% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 92.074% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 85.405% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -60.438% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 40.681% |
| Neutra Corp. | 973.52 Thousand USD | -233.786% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 88.801% |
| PureTech Health plc | 125.58 Million USD | 97.412% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 13.511% |
| IXICO plc | 1.9 Million USD | -71.0% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 84.171% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 96.855% |
| CSL Limited | 18.62 Billion USD | 99.983% |
| Cellectis S.A. | 249.36 Million USD | 98.697% |